|Day Low/High||19.61 / 20.89|
|52 Wk Low/High||17.89 / 52.74|
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
But don't buy into this overheated market right as Canada legalizes, wait until prices come down -- which they will.
There just isn't any worry right now that this market is going to start moving back up with conviction.
Will it be too painful to stick around while you wait for the Fed to change course?
This is a stock with a terrible chart and questionable financials.
The time to scoop up Altria is now, not when some type of official announcement is made.
These stocks offer some diversification or unique features in the legal-weed space.
Canopy Growth could be Constellation's next big growth engine.
Shareholders enjoyed a crisp day of gains after Constellation cracked open a great earnings report pre-market.
Investors and experts need more time before they go all in on cannabis.
Market experts are abuzz over Constellation's potential new inroads into the cannabis market.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
I have no problem blessing an investment in this name with the appropriate steps taken toward risk management.
Constellation looks to wine, beer, and cannabis to take it higher.
There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.
I have the honor and pleasure of book-ending your week away from Doug. On Friday, we'll get non-farm payroll and the unemployment, so I don't put much stock in the data coming this Thursday morning. Instead, I want to start off the day talking abou...
Constellation looks like a star today after beating expectations.
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
Expert says weed-related products for pets could become a $55 billion-a-year business.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
A look at CGC's charts and our latest strategy.
'There's too much hype too soon,' Canopy Growth chief Bruce Linton says.
Covered calls may be the best bet -- or wait for a dip.